Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27083547 | 1.00 | GRM5 (0.40) | GRM5GRM4HPGDMEN1LMNA | |
| SCHEMBL24156699 | 1.00 | GRM5 (0.40) | GRM5GRM4HPGDMEN1LMNA | |
| SCHEMBL24156098 | 0.86 | GRM5 (0.36) | GRM5 | |
| SCHEMBL27083572 | 0.86 | GRM5 (0.36) | GRM5 | |
| SCHEMBL24156083 | 0.86 | GRM5 (0.36) | GRM5 | |
| SCHEMBL27083526 | 0.83 | GRM5 (0.37) | GRM5LMNASMN1; SMN2 | |
| SCHEMBL24156618 | 0.83 | GRM5 (0.37) | GRM5LMNASMN1; SMN2 | |
| SCHEMBL24156399 | 0.83 | GRM5 (0.37) | GRM5LMNASMN1; SMN2 | |
| SCHEMBL31543584 | 0.78 | GRM5 (0.43) | GRM5GRM4 | |
| SCHEMBL32667230 | 0.75 | CHRNB2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043435-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2024-02-08 | — | — | US | disclosed |
| CN-115715288-A | TYK-2 inhibitors | 百济神州有限公司 | 2023-02-24 | — | — | CN | disclosed |
| WO-2021259208-A1 | TYK-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043435-A1 | TYK-2 INHIBITOR | TYK2, IRAK2, PTK2B | GRM5 3512/4885GRM4 3802/4885HPGD 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.